L-Carnitine supplementation attenuates lenvatinib-induced muscle impairment without diminishing its anti-angiogenesis efficacy

[Aim] Lenvatinib (LEN), an oral tyrosine kinase inhibitor, is widely used to treat several types of advanced cancers but often causes muscular adverse reactions. Our previous study revealed that LEN reduces L-carnitine (L-CAR) content, expression of carnitine-related genes, and mitochondrial function in the skeletal muscle. Therefore, the present study aimed to investigate whether L-CAR supplementation prevents LEN-induced muscle impairment without affecting its anti-angiogenesis effect.